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The anti-cancer chemotherapeutic potential of novel platinum(II) complexes of salicylate derivatives 
[Pt(dppe)(SA)2, Pt(dppm)(SA)2] and fumaric acid [Pt(dppe)(FU)2] were determined, using two cancer cell 
lines, breast cancer (MCF-7) and glioma cells (C6). IC50 values of the three compounds were lower in the 
cisplatin-resistant cell type C6 cell lines than in MCF-7 cells.  
 





Cisplatin [cis-diamminedichloroplatinum(II)] was 
introduced into clinical practice in the early 1970s and it is 
one of the most active antineoplastic agents currently 
used in medical oncology (Barbara et al., 2006). Over the 
years, thousands of cisplatin analogues have been 
synthesized, varying the nature of the leaving groups and 
the carrier ligand (Matesanza and Souza, 2007; 
Rosenberg et al., 1969). Despite the large amount of 
compounds synthesized and tested, only a small number 
have advanced to the late stages of clinical development, 
that is the second-generation platinum drug carboplatin is 
in routine clinical use (Wang et al., 2002).  
Cisplatin is the best example of metal complexes and 
binds to DNA by coordination of the Pt atom to the N7 
positions of two guanine bases or to adenine and 
guanine, which then block replication and/or prevent 
transcription. Non-covalent interactions between metal 
complexes and DNA include hydrogen bonding, electro-
static interaction and intercalation (Rebolledo et al., 2005; 
Kovala-Demertzi et al., 2003; Padhye et al., 2005). 
Cisplatin has a broad spectrum of activity against 
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curative regimens in testicular and ovarian cancers, 
demonstrating significant activity also against lung, head 
and neck, esophagus, bladder, cervix, and endometrial 
cancers (Elwell et al., 2006). Although cisplatin is one of 
the most frequently used chemotherapeutics in the 
treatment of many tumors, the clinical application of 
cisplatin is greatly limited by its toxicity, narrow range of 
activity, both intrinsic and acquired resistance, and low 
aqueous solubility (Cui et al., 2006).  
In recent years, there has been an emergence of new 
structural types of compounds often with promising 
activity and able to circumvent cisplatin resistance (Van 
der Schilden et al., 2004; Perez et al., 2001; Kasparkova 
et al., 2003). The majority of platinum complexes 
exhibiting anti-tumor activity have two cis-leaving ligands, 
such as chlorides and two strongly bonded, relatively 
inert amine type systems (non-leaving ligands) 
(Ciesielska et al., 2006; Reedijk,1992). A few different 
liposomal formulations of cisplatin have also been 
prepared and biologically evaluated since the introduction 
of cisplatin. Nevertheless, so far none of liposomal 
formulations of cisplatin have been approved for the 
clinical use in the world. The key reasons are the poor 
water solubility and low lipophilicity of cisplatin, which 
make it difficult to efficiently encapsulate the drug in a 
liposome.  An   alternative   approach   is   to   synthesize 
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lipophilic complexes. In addition, any work carried out in 
this field can be concluded that even small variations in 
the amine ligands of cisplatin analogues have already 
huge effects on the activity of the complexes. Zutphen et 
al. (2005) reported that new cisplatin compound 
composed of methylamine located cis to aminoethanol 
that posses promising cytotoxic activity (Abine Van Rijta 
et al., 2006; Van Zutphen et al., 2005). Some studies 
have demonstrated that Dppe as non leaving ligand has 
in vitro cytotoxic and in vivo antitumor activity for silver 
(Au-based) drugs (Berners-Price et al., 1986; Snyder et 
al., 1986; Mirabelli et al., 1985). 
Therefore, the reduction of essential cellular com-
ponents or the generation of reactive radical species 
during phosphine oxidation, perhaps involving redox-
active metal ions such as copper and iron may play a role 
in the cytotoxic activity of Dppe.  
 
 
MATERIALS AND METHODS 
 
Synthesis of complexes  
 
For preparing Platinum(II) complexes, PtCl2COD (where COD is 1.5 
cyclooctadiene)   was  used  as  the  main   starting   material    and  
PtCl2(dppx) (where dppx is bis (diphenyl phosphino) methane and 
1,2 bis (diphenyl phosphino) ethane) complexes were also used as 
the following starting materials. All the compounds synthesized and 
tested for in vitro antitumor activity were given in Figure 1. 
Pt(dppe)(SA)2 (Figure 1A), Pt(dppm)(SA)2 (Figure 1B) and 
Pt(dppe)(FU)2 (Figure 1C) were synthesized under the nitrogen 
atmosphere according to reported methods (Nakiboglu, 2006). All 
complexes were characterized by elemental analysis and 
spectroscopic techniques namely FTIR and 31P{H} NMR ( 31P, 
J
P Pt31 195
). Formula weights and melting points for complex 1 
(Figure 1A) (PtC40H34O6P2.1/2CH2Cl2) is: 909.74 g and 188ºC. 
Analysis Calculated for complex 1 is: C, 53.42 and; H, 3.88. Found: 
C, 54.34 and; H, 3.90. Formula weights and melting points for 
complex 2 (Figure 1B) (PtC39H32O6P2.1.5CH2Cl2) is: 980.73 g and 
206ºC. Analysis Calculated for complex 2 is: C, 49.59 and; H, 3.57. 
Found: C, 49.67 and; H, 3.40. Formula weights and melting points 
for complex 3 (Figure 1c) (PtC34H30O8P2) is: 823.89 g and 204ºC. 
Analysis Calculated for complex 3 is: C, 49.56 and; H, 3.64. Found: 
C, 49.41and; H, 4.04. IR spectra demonstrated the characteristic 
patterns expected from carboxylate ligands.  
The υa (COO
-) and υs (COO
-) bands for complex 1 is: 1530 to 
1610 cm-1 and 1390 cm-1; for complex 2 is 1560 to 1650 cm-1 and 
1390 cm-1; for complex 3 is 1540 to 1660 cm-1 and 1410 cm-1. 
31P{1H} NMR spectral data of the platinum complexes further 
support the structure of aforementioned complexes. 31P{1H} NMR 
spectra were recorded on a JOEL JNM-Ex400 spectrometer. They 
were measured in methanol (CD3OD) solutions and 85% H3PO4 
served as an external reference. NMR grade solvents were used for 
 




nuclear magnetic resonance (NMR) analysis. All platinum 
complexes give a triplet on the NMR spectra. This triplet of the 31P 
spectrum is due to the coupling of platinum atom with two 
phosphorus atoms. The coupling constant, JP-Pt, ranges from 3200 
to 3985 Hz, which is typical for platinum(II) complexes containing 
two phosphorus and two oxygen donors. 31P spectra of the 
carboxylate complexes are very similar to those of chlorides starting 
complexes, but the carboxylate complexes exhibit a large shift of 
the 31P resonance relative to that of the chlorides. Because of the 
platinum-oxygen bond being weaker than platinum-chloride bond, 
the chemical shift values of starting complexes shifted to higher 
field. δP (ppm) and JP-Pt value for complex 1 is: +32.0 ppm and 
3985.5 Hz; for complex 2 is: -67.0 ppm and 3390.0 Hz and; 
complex 3 is: +41.7 ppm and 3607.8 Hz.  
 
 
Cell lines and cytotoxicity  
 
MCF-7 mammary cancer cells and C6 rat glioma cancer cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 100 U/ml Penicilin, 10 ug/ml Streptomycin, 2mM 
L-glutamine and 10% HI- Fetal Calf Serum (FCS) at 37ºC in a 
humidified 5% CO2 incubator.  
Cell viability was determined by MTT [3-(4,5-dimethylthiazole-2-
yl)-2,5-diphenyl tetrazolium bromide] assay. 5 × 103 cells per well 
were plated onto 96-well sterile for 24 h. Cells were incubated with 
various concentrations, ranging from 0 to 400 μM of the compounds 
tested freshly, and dissolved in  dimethyl sulfoxide (DMSO) for 24, 
48 and 72 h at 37°C. Then, the cells were fixed by adding 20 μl of 
MTT (5 mg/ml) per well, and incubated for 4 h at 37°C. 
Subsequently, the medium containing MTT was removed, and 100 
μl of acidified isopropanol (0.04 N HCl) added. Spectrophotometric 
absorbance of each sample was measured at 550 nm, using a 
micro plate reader (Bio-Tek, model powerwave XS). 
All cytotoxicity experiments were performed in triplicate. The 50% 
inhibitory dose (IC50) was defined as the drug concentration that 
reduced the number of living cells to 50%:  
 
Inhibition (%) = [1 - (T/C)] × 100 
 
Where, T is the mean absorbance of the treated cells and C is the 
mean absorbance in the controls.  
For comparison purposes, the cytotoxicity of cisplatin was 
evaluated under the same experimental conditions.  
 
 
Statistical analysis  
 
Statistical analysis was evaluated by one-way ANOVA. P < 0.05 
was accepted as significant difference. 
 
 
RESULTS AND DISCUSSION 
 
The ligand exchange reactions of leaving groups of 
platinum complexes with biological nucleophiles are likely 
governing their antitumour and toxic properties. The 
nephrotoxicity, gastrointestinal toxicity and possible bone 
narrow suppression, induced by platinum based 
antitumour agents, might be attributed to ligand exchange 
reactions of platinum with sulfydryl groups, and the 
subsequent inactivation of essential enzymes and other 





react with the series of peptide and proteins from 
glutathione, metallothionein to plasma proteins by binding 
to sulfhydryl groups (Hall and Hambley, 2002). In this 
respect, some research proposes that fumaric acid esters 
also react with sulfhydryl groups in proteins. Therefore, 
besides others, fumaric acid esters are interesting for 
their antipsoriatic activity (Frycak et al., 2005). Complex 3 
was synthesized using fumaric acid as a leaving group. 
Another leaving group was salicylate that is important 
nonsteroidal anti-inflammatory agents (Figure 1A and B). 
It has been well known that they can block metastasis of 
cancer cells by inhibiting synthesis of the prostaglandins 
(Ye et al., 2007).  
Sodium salicylate is a drug widely used all over the 
world, initially in the form of aspirin (acetyl salicylate) 
which is rapidly converted to salicylate in the organism. 
Although it has few side effects, it can cause changes in 
the hearing system (Jastreboff and Sasaki, 1994; Garetz 
and Schacht, 1996). Particularly, Li et al. (2002) using a 
rat experimental model, observed significant oto-
protection by sodium salicylate against the cytotoxic 
effects of cisplatin, as demonstrated by the brain stem 
auditory potentials, without affecting the antitumoral 
potency of cisplatin. As for non-leaving group, 1,2-
bis(diphenylphosphino)ethane (dppe) and 1,2-
bis(diphenylphosphino)methane were used. Dppe and a 
number of closely related diphosphines have potent 
cytotoxicity to tumor cells in culture including P388 
leukemia, M5076 reticulum cell sarcoma, B16 melanoma, 
and the mammary adenocarcinoma and have 
reproducible activity in animal tumor models. Some 
investigator has reported that some gold-phospine 
compounds exhibit potent ligand-mediated cytotoxicity (Li 
et al., 2006). All the design strategies in our research are 
to develop platinum complexes with expectations of 
higher liposolubility and chemical stability, along with 
higher anti-tumor activities.  
The solubility of the complexes, both in water and 
organic solvents such as ethanol, acetone and ether was 
determined. Three compounds, Pt(dppe)(SA)2, Pt(dppm) 
(SA)2, and Pt(dppe)(FU)2, were not water soluble. 
Dimethyl sulfoxide (DMSO) was used for dissolving the 
complex, and in each experiment, controls with 
appropriate concentrations of vehicle were performed. 
Concentrations of compounds were ranging from 0, 1 to 
100 M. The compounds were then filter-sterilized and 
stored at room temperature. The new platinum(II) 
complexes were tested for their cytotoxicity by MTT 
assay on cancer cell lines, human breast carcinoma cell 
line, MCF-7 and rat C6 glioma cells as a model of astro-
cytomas (Mosmann, 1983). In attempting to evaluate the 
cyto-selective nature of these test agents and provide the 
best possible means of comparison, we selected two 
different model cell lines. In addition, it is worth noting 
that these two neoplastic cells are not identical in origin, 
since    their   media   requirements  and  growth  kinetics  
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Figure 2. Time and dose dependent cytotoxic effects of cisplatin and newly synthesized cisplatin complexes Pt(dppe)(FU)2,  
Pt(dppe)(SA)2 and Pt(dppm)(SA)2 on C6 cells for 24, 48 and 72 h. Cell viability was evaluated by the MTT colorimetric assay at 




differ. C6 cells represent a model of astrocytomas that 
are the most common tumors of the central nervous 
system (CNS), usually with a poor prognosis, and extre-
mely difficult to treat (Poppenborg, 1999). Otherwise, 
MCF-7 cells represent breast cancer cell type. Hence, 
there remains the possibility that these factors may 
contribute to the apparent non-selective nature of the test 
agents.  
MCF-7 and C6 cells were exposed to four different 
concentrations of the compounds [Pt(dppe)(SA)2, 
Pt(dppm)(SA)2, and Pt(dppe)(FU)2] for 24, 48 and 72 h, 
respectively (Figures 2 and 3). The relative potency of 
these test agents was determined by the inclusion of one 
of the best known and most biologically active metal-
based anti-cancer agent, cisplatin.  
Pt(dppe)(FU)2, in C6 and MCF-7 cells exhibit dose 
dependent cytotoxicities in all time intervals (Figures 2A 
and 3A). The cell growth inhibition in C6 cells  diminished 
at the level of 30 μM since the doses above this 
concentration led to DMSO or compound dependent cell 
death. As seen IC50 values in Table 1, C6 cells is more 
sensitive than MCF-7 cells for this compound. Similarly, 
IC50 values of Pt(dppe)(SA)2 exhibited the most cytotoxic 
effect in C6 cells compared to MCF-7 cells (Table 1). 
However, at 72 h incubation time, 30 µM of the 
compound reached the maximum cytotoxic effect as the 
cells went to death due to high DMSO concentration 
(Figure 2B). In MCF-7, at the beginning of the incubation, 
Pt(dppe)(SA)2 has led to the cell proliferation at 24 h 
incubation and, then, this effect turned to inhibition effect 
(Figure 3B).  
Pt(dppm)(SA)2 is different from the complex 1 as non 
leaving group (Figure 1A). Therefore, the effect of “dppm” 
could be specifically evaluated. This compound inhibited 
cell proliferation up to 50% at 72 h incubation period in 
C6 cells (Figure 2C).  Similarly   with   other   compounds, 
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Figure 3. Time and dose dependent cytotoxic effects of cisplatin and newly synthesized cisplatin complexes Pt(dppe)(FU)2,  Pt(dppe)(SA)2 




Table 1. IC50 values of cisplatin and  synthesized Platinum(II) complexes at 72 h. 
 
Compound 
Cytotoxicity in MCF-7  
(IC50, g/ml) 
Cytotoxicity in C6 
 (IC50, g/ml) 
Cisplatin 1.56 16.75 
Pt(dppe)(SA)2 129.96 27.74 
Pt(dppm)(SA)2 81.90 23.97 




upon 72 h incubation of Pt(dppm)(SA)2, inhibition effect 
was not able to be detected anymore, due to the excess 
cell death after 30 μM (Figure 2C). In MCF-7 cells, the 
inhibition effect of Pt(dppm)(SA)2 compound could be 
obtained up to 100 μM (Figure 3C). The corresponding 
IC50 values demonstrated that this compound is more 
cytotoxic in C6 cells than those of MCF-7 cells (Table 1). 
Table 1 shows that the cytotoxicity of Pt(dppm)(SA)2 is 
very close to that of cisplatin against C6 cells. In MCF-7 
cells, Pt(dppm)(SA)2 has the more cytotoxicity than 
compound Pt(dppe)(SA)2. This could be due to the 
difference of a non leaving group. As a non leaving 
group, phospine ligands have been used for the all three 
compounds. Our compounds with salicylic acid (Figure 
1A and B) exhibited the most cytotoxic effect to C6 cells. 






that C6 glioma cell was most sensitive to our compounds. 
The cytotoxicity of compounds Figures 1A, B and C) 
against C6 cells was comparable to that of cisplatin 
(Figure 1; Table 1). 
The most effective inhibition of cisplatin was found in 
MCF-7 cells suggesting that, in general, cells of breast 
origin may be more sensitive than glial cells for cisplatin. 
Interestingly, IC50 values for the three compounds were 
lower in the cisplatin resistant cell type C6 cell lines, than 
in MCF-7cells. Therefore, it may be possible that our test 
agents do display a degree of selectivity for one cancer 
cell type over another. In fact, cyto-selectivity is a highly 
desirable characteristic for all anti-cancer agents. It is 
often difficult to achieve, even with cisplatin, a drug 
currently in clinical use to the patient’s needs. 
In conclusion, all three compounds, Pt(dppe)(SA)2, 
Pt(dppm)(SA)2, and Pt(dppe)(FU)2, seem to be very 
efficient as a cytotoxic agent against astrocytomas in 
vitro. Further investigation about its mechanism of action, 
as well as exploration of its capability to restrain tumor 
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